- Accelerating partnership talks with global big pharmaceutical firms on ADC platforms and pipeline assets
- Platform competitiveness validated by consecutive positive ADC clinical results… Active new and follow-up partner meetings planned
[by Kang, In Hyo] 라이트닝 바카라 사이트 Biosciences announced on January 6 that it has received an official invitation to participate in the 44th JP Morgan Healthcare Conference 2026, the world's largest pharmaceutical and biotechnology investment forum, scheduled to be held in San Francisco, U.S., from January 12 to 15 (local time).
As an official invitee, 라이트닝 바카라 사이트 Biosciences plans to showcase its proprietary antibody-drug conjugate (ADC) platform and novel drug candidates to major global pharmaceutical companies while engaging in discussions on potential technology licensing opportunities. The company explained that the primary objective of its participation is to further advance and deepen partnership negotiations with multinational pharmaceutical companies, drawing on the proven technological strength of its ConjuAll ADC platform, which has delivered meaningful clinical outcomes in global clinical trials.
라이트닝 바카라 사이트 Biosciences has recently drawn significant global attention following a series of successful clinical data from its key out-licensed pipeline assets. For instance, the HER2-targeting ADC, 'IKS014 (LCB14),' demonstrated favorable efficacy and safety profiles in a global Phase 1 clinical trial and has been positioned as a potential post-Enhertu therapeutic option, a key topic in the evolving HER2-targeted ADC market. In addition, the ROR1-targeting ADC, 'CS5001 (LCB71),' became the first agent in its class to demonstrate clinical efficacy not only in hematological malignancies but also in solid tumors, while exhibiting superior efficacy and safety compared to competing ROR1- targeted ADCs currently under development.
The company explained that, on the back of these recent clinical achievements, inquiries from global pharmaceutical companies seeking to leverage its ADC platform technology and novel drug candidates have increased significantly compared with the previous year. Accordingly, the company plans to conduct in-depth follow-up discussions with existing potential partners during the 라이트닝 바카라 사이트, while simultaneously engaging in active partnering negotiations with additional multinational pharmaceutical companies expressing interest in adopting the platform technology.
Through these meetings, LigaChem Biosciences plans to actively showcase the technological value of its next-generation ADC components, including linkers and proprietary payloads. In particular, this time, the company intends to highlight the competitiveness of its proprietary ‘PBD prodrug’ payload technology, alongside newly developed ADC linkers and payload candidates such as its ‘next-generation topoisomerase I inhibitor (Topo1i) payload,’ which is designed to overcome resistance mechanisms associated with currently marketed or clinically developed Topo1i-based payloads. Against the backdrop of intensifying global competition in the ADC market, LigaChem Biosciences emphasized that its clinically validated platform technology represents a highly attractive option for numerous potential partners.
"Through our participation in the JP Morgan Healthcare Conference, we intend to demonstrate that our technology has progressed beyond a transient expectation and is now firmly recognized as a global benchmark,” said Park Se-jin, COO and CFO of LigaChem Biosciences. “As a series of positive clinical results has reinforced the credibility of our platform, we will leverage this conference to accelerate ongoing technology transfer discussions and translate them into concrete results," he added.